Prostate cancer screening. Recommendations of the Association Française d'Urologie (AFU);Dépistage du cancer de la prostate. Recommandations de l'Association Française d'Urologie (AFU)

Progres en Urologie

Volumn 13, Issue 2, 2003, Pages 209-214

  Villers, Arnauld ^b   Rébillard, Xavier ^b   Soulié, Michel ^b   Davin, Jean Louis ^a   Coloby, Patrick ^b   Moreau, Jean Luc ^b   Mejean, Arnaud ^b   Irani, Jacques ^b   Coulange, Christian ^b   Mangin, Philippe ^b  

^a CCAFU   (France)

^b NONE

Author keywords

Cancer; Guideline; Prostate; PSA; Screening

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

CANCER SCREENING; CAUSE OF DEATH; DIGITAL RECTAL EXAMINATION; ETHNIC GROUP; FAMILY HISTORY; GENERAL PRACTITIONER; HUMAN; LIFE EXPECTANCY; ONCOLOGY; PATHOLOGIST; PROSTATE CANCER; RADIOLOGIST; REVIEW; RISK FACTOR; UROLOGY; ARTICLE; BLOOD; HEALTH CARE QUALITY; MALE; MASS SCREENING; MORTALITY; PRACTICE GUIDELINE; PROSTATE TUMOR; STANDARD;

HUMANS; MALE; MASS SCREENING; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; QUALITY ASSURANCE, HEALTH CARE;

EID: 0041708424     PISSN: 11667087     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (41)

1. ANAES : Opportunité d'un dépistage de masse du cancer de la prostate par le dosage du PSA. Paris 1998.
2. AUS G., HUGOSSON J., NORLÉN L.: Long-term survival and mortality in prostate cancer treated with non curative intent. J. Urol., 1995, 154, 460-465.
3. BABAIAN R.J., JOHNSTON D.A., NACCARATO W., AYALA A., BHADKAMKAR V.A., FRITSCHE H.A. Jr. : The incidence of prostate cancer in a screening population with a serum prostate specific antigen between 2.5 and 4.0 ng/ml : relation to biopsy strategy. J. Urol., 2001, 65, 757-760.
4. BARTSCH G., HORNINGER W., KLOCKER H., REISSIGL A., OBERAIGNER W., SCHONITZER D., SEVERI G., ROBERTSON C., BOYLE P., Tyrol Prostate Cancer Screening Group : Prostate cancer mortality after introduction of prostate-specific antigen mass screening in the Federal State of Tyrol, Austria. Urology, 2001, 58, 417-424.
5. CARROLL P., COLEY C., McLEOD D., SCHELLHAMMER P., SWEAT G., WASSON J., ZIETMAN A., THOMPSON I. : Prostate-specific antigen best practice policy - part I : Early detection and diagnosis of prostate cancer. Urology, 2001, 57, 217-224.
6. CARROLL P.R. : Serum prostate-specific antigen for prostate cancer early detection : Total, free, age-stratified, or complexed? Urology, 2001, 57, 591-603.
7. CARTER H.B., EPSTEIN J.I., CHAN D.W., FOZARD J.L. AND PEARSON J.D. : Recommended prostate-specific antigen testing intervals for the detection of curable prostate cancer. JAMA, 1997, 277, 1456-1460.
8. CARTER H.B., PEARSON J.D. : Prostate-specific antigen velocity and repeated measures of prostate-specific antigen. Urol. Clin. North Am., 1997, 24, 333-338.
9. CARTER H.B. : A PSA threshold of 4.0 ng/mL for early detection of prostate cancer: the only rational approach for men 50 years old and older. Urology, 2000, 55, 796-799.
10. CATALONA W.J., RICHIE J.P., AHMANN F.R., HUDSON M.A., SCARDINO P.T., FLANIGAN R.C., DEKERNION J.B., RATLIFF T.L., KAVOUSSI L.R., DALKIN B.L., et al. : Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J. Urol., 1994, 151, 1283-1290.
11. CATALONA W.J. Screening for prostate cancer. JAMA, 1995, 273, 289-294.
12. CATALONA W.J., PARTIN A.W., SLAWIN K.M., BRAWER M.K., FLANIGAN R.C., PATEL A., RICHIE J.P., DEKERNION J.B., WALSH P.C., SCARDINO P.T., LANGE P.H., SUBONG E.N., PARSON R.E., GASIOR G.H., LOVELAND K.G., SOUTHWICK P.C. : Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA, 1998, 279, 1542-1547.
13. CHAUVET B., VILLERS A., DAVIN J.L., NAHON S. : Actualités sur le dépistage, le diagnostic et le traitement des cancers de prostate. Bull. Cancer, 2002, 89, 37-45.
14. COOKSON M.M. : Prostate cancer: screening and early detection. Cancer Control, 2001, 133-140.
15. D'AMICO A.V., WHITTINGTON R., MALKOWICZ S.B., RENSHAW A.A., TOMASZEWSKI J.E., BENTLEY C., SCHULTZ D., ROCHA S., WEIN A., RICHIE J.P. :Estimating the impact on prostate cancer mortality of incorporating prostate-specific antigen testing into screening. Urology, 2001, 58, 406-410.
16. DE KONING H.J., LIEM M.K., BAAN C.A., BOER R., SCHRODER F.H., ALEXANDER F.E. ERSPC : Prostate cancer mortality reduction by screening : power and time frame with complete enrollment in the european randomised screening for prostate cancer (ERSPC) trial. Int. J. Cancer, 2002, 98, 268-273.
17. DE LA TAILLE A., HOULGATTE A., HOUDELETTE P., BERLIZOT P., FOURNIER R., RICORDEL I. : Incidence de la variabilité du rapport PSA libre/PSA total sur le diagnostic précoce du cancer de la prostate. Prog Urol 1997; 7(3):455-463.
18. FANG J., METTER E.J., LANDIS P., CHAN D.W., MORRELL C.H., CARTER H.B.. : Low levels of prostate-specific antigen predict long-term risk of prostate cancer : results from the Baltimore Longitudinal Study of Aging. Urology, 2001, 58, 411-416.
19. FARKAS A., SCHNEIDER D., PERROTTI M., CUMMINGS K.B., WARD W.S. : National trends in the epidemiology of prostate cancer, 1973 to 1994: evidence for the effectiveness of prostate-specific antigen screening. Urology, 1998, 52, 444-448; discussion 448-449.
20. GILLILAND F.D., HUNT W.C., KEY C.R.. : Improving survival for patients with prostate cancer diagnosed in the prostate-specific antigen ERA. Urology, 1996, 48, 67-71.
21. HANKEY B.F., FEUER E.J., CLEGG L.X., HAYES R.B., LEGLER J.M., PROROK P.C., RIES L.A., MERRILL R.M., KAPLAN R.S.. : Cancer surveillance series: interpreting trends in prostate cancer - part I: Evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates. J. Natl. Cancer Inst., 1999, 91, 1017-1024.
22. HOLMBERG L., BILL-AXELSON A., HELGESEN F., SALO J.O., FOLMERZ P., HAGGMAN M., ANDERSSON S.O., SPANGBERG A., BUSCH C., NORDLING S., PALMGREN J., ADAMI H.O., JOHANSSON J.E., NORLEN B.J., Scandinavian Prostatic Cancer Group Study Number 4 : A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N. Engl. J. Med., 2002, 347, 781-789.
23. KRUMHOLTZ J., CARVALHAL G., RAMOS C., SMITH D., THORSON P., YAN Y., HUMPHREY P., ROEHL K., CATALONA W. : Prostate-specific antigen cutoff of 2.6 ng/mL for prostate cancer screening is associated with favorable pathologic tumor features. Urology. 2002, 60, 469-473; discussion 473-474.
24. LABRIE F., CANDAS B., DUPONT A., CUSAN L., GOMEZ J.L., SUBURU R.E., DIAMOND P., LEVESQUE J., BELANGER A. : Screening decreases prostate cancer death: first analysis of the 1988 Quebec prospective randomized controlled trial. Prostate, 1999, 38, 83-91.
25. POTTER S.R., HORNIGER W., TINZL M., BARTSCH G., PARTIN A.W. : Age, prostate-specific antigen, and digital rectal examination as determinants of the probability of having prostate cancer. Urology, 2001, 57, 1100-1104.
26. PROROK P.C., ANDRIOLE G.L., BRESALIER R.S., BUYS S.S., CHIA D., CRAWFORD E.D., FOGEL R., GELMANN E.P., GILBERT F., HASSON M.A., HAYES R.B., JOHNSON C.C., MANDEL J.S., OBERMAN A., O'BRIEN B., OKEN M.M., RAFLA S., REDING D., RUTT W., WEISSFELD J.L., YOKOCHI L., GOHAGAN J.K. : Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial Project Team. Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Control Clin. Trials, 2000, 21(6 Suppl), 273-309.
27. RAVERY V., JAVERLIAT I., TOUBLANC M., BOCCON-GIBOD L., DELMAS V., BOCCON-GIBOD L. : Caractéristiques des cancers prostatiques chez les français d'origine afro-antillaise. Prog. Urol., 2000, 10, 231-236.
28. REMONTET L., ESTÈVE J., BOUVIER A.M., P GROSCLAUDE et coll. Incidence et mortalité des cancers en France 1978-2000. RESP, 2003 (sous presse).
29. ROBERTS R.O., BERGSTRALH E.J., KATUSIC S.K., LIEBER M.M., JACOBSEN S.J. : Decline in prostate cancer mortality from 1980 to 1997, and an update on incidence trends in Olmsted County, Minnesota. J. Urol., 1999, 161, 529-533.
30. SCHRODER F.H., BANGMA C.H. : The European Randomized Study of Screening for Prostate Cancer (ERSPC). Br. J. Urol., 1997, 79, Suppl. 1, 68-71.
31. SCHRÖDER F.H., KRANSE R., RIETBERGEN J.B.W., HOEDEMAEKER R.F., KIRKELS W.J. and members of the ERSPC, section Rotterdam : The European Randomized Study of Screening for Prostate Cancer (ERSPC) : an Update. Eur. Urol., 1999, 35, 539-543.
32. SCHRÖDER F.H., ALEXANDER F.E., BANGMA C.H.H., HUGOSSON J., SMITH D.S. : Screening and early detection of prostate cancer. Prostate, 2000, 44, 255-263.
33. SCHRÖDER F.H. : Diagnosis, characterization and potential clinical relevance of prostate cancer detected at low PSA ranges. Eur. Urol., 2001, 39, Suppl. 4, 49-53.
34. SOULIE M., VILLERS A., RICHAUD ., PRAPOTNICH D., RUFFION A., GROSCLAUDE P. : La morbidité compétitive et son impact sur l'espérance de vie dans la décision thérapeutique du cancer localisé de la prostate. Prog. Urol., 2001, 11, 1195-1204.
35. STAMEY T.A., JOHNSTONE I.M., McNEAL J.E., LU A..Y, YEMOTO C.M. : Preoperative serum prostate specific antigen levels between 2 and 22 ng./ml. correlate poorly with post-radical prostatectomy cancer morphology: prostate specific antigen cure rates appear constant between 2 and 9 ng./ml. J. Urol., 2002, 167, 103-111.
36. VALERI A., CORMIER L., MOINEAU M.P., CANCEL-TASSIN G., AZZOUZI R., DOUCET L., BASCHET F., CUSSENOT I., L'HER J., BERTHON P., MANGIN P., CUSSENOT O., MORIN J.F., FOURNIER G. : Targeted screening for prostate cancer in high risk families: early onset is a significant risk factor for disease in first degree relatives. J. Urol., 2002, 168, 483-487.
37. VILLERS A., GROSCLAUDE P., HAILLOT O., ABBOU C.C., RICHARD F., BOCCON-GIBOD L.: Dépistage du Cancer de la Prostate (1) : Évolution des connaissances et des pratiques depuis la conférence de consensus de 1989. Prog. Urol., 1997, 7, 508-515.
38. VILLERS A., SOULIE M., HAILLOT O., BOCCON-GIBOD L. : Dépistage du Cancer de la Prostate (3) : Facteurs de risque, Histoire naturelle, évolution sans traitement. Caractéristiques des cancers dépistés. Prog. Urol., 1997, 7, 655-661.
39. VILLERS A., CHAUTARD D.: PSA libre : l'utilisation en routine est prématurée pour le dépistage du cancer de prostate. Prog. Urol., 2000, 10, 618-621.
40. VILLERS A., MALAVAUD B., SOULIÉ M., GROSCLAUDE P., FERNET P., TENAILLON M., RIEU J.P., SALAMA G., HACKER P. : Participation française à l'étude européenne de dépistage randomisé du cancer de la prostate par le dosage sérique du PSA. Etude de faisabilité. 2070 hommes inclus. Résultats du PSA et du taux de détection des 391 hommes ayant participé. Prog. Urol., 2002, 12, supp. 2, 53.
41. WOODRUM D.L., BRAWER M.K., PARTIN A.W., CATALONA W.J., SOUTHWICK P.C. : Interpretation of free prostate specific-antigen clinical research studies for the detection of prostate cancer. J. Urol., 1998, 159, 5-12.